BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30028443)

  • 21. Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm.
    Goh BK; Ooi LL; Kumarasinghe MP; Tan YM; Cheow PC; Chow PK; Chung YF; Wong WK
    Pancreatology; 2006; 6(6):520-6. PubMed ID: 17124434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas.
    Basturk O; Chung SM; Hruban RH; Adsay NV; Askan G; Iacobuzio-Donahue C; Balci S; Zee SY; Memis B; Shia J; Klimstra DS
    Virchows Arch; 2016 Nov; 469(5):523-532. PubMed ID: 27591765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic accuracy of diffusion restriction in intraductal papillary mucinous neoplasm of the pancreas in comparison with "high-risk stigmata" of the 2012 international consensus guidelines for prediction of the malignancy and invasiveness.
    Kim M; Mi Jang K; Kim SH; Doo Song K; Jeong WK; Kang TW; Kim YK; Cha DI; Kim K; Yoo H
    Acta Radiol; 2017 Oct; 58(10):1157-1166. PubMed ID: 28084815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas.
    Oda Y; Aishima S; Morimatsu K; Hayashi A; Shindo K; Fujino M; Mizuuchi Y; Hattori M; Tanaka M; Oda Y
    Hum Pathol; 2013 Aug; 44(8):1487-98. PubMed ID: 23465281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased SOX9 Expression in Premalignant and Malignant Pancreatic Neoplasms.
    Gnerlich JL; Ding X; Joyce C; Turner K; Johnson CD; Chen H; Abood GJ; Pappas SG; Aranha GV
    Ann Surg Oncol; 2019 Feb; 26(2):628-634. PubMed ID: 30357576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CT and MR imaging features of fistulas from intraductal papillary mucinous neoplasms of the pancreas to adjacent organs: A retrospective study of 423 patients.
    Ravaud S; Laurent V; Jausset F; Cannard L; Mandry D; Oliver A; Claudon M
    Eur J Radiol; 2015 Nov; 84(11):2080-8. PubMed ID: 26321495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.
    Pea A; Yu J; Rezaee N; Luchini C; He J; Dal Molin M; Griffin JF; Fedor H; Fesharakizadeh S; Salvia R; Weiss MJ; Bassi C; Cameron JL; Zheng L; Scarpa A; Hruban RH; Lennon AM; Goggins M; Wolfgang CL; Wood LD
    Ann Surg; 2017 Jul; 266(1):133-141. PubMed ID: 27433916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CT attenuation of unilocular pancreatic cystic lesions to differentiate pseudocysts from mucin-containing cysts.
    Chalian H; Töre HG; Miller FH; Yaghmai V
    JOP; 2011 Jul; 12(4):384-8. PubMed ID: 21737901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas.
    Ikenaga N; Ohuchida K; Mizumoto K; Yu J; Kayashima T; Hayashi A; Nakata K; Tanaka M
    Hum Pathol; 2010 Oct; 41(10):1466-74. PubMed ID: 20619441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas.
    Mito K; Saito M; Morita K; Maetani I; Sata N; Mieno M; Fukushima N
    Pancreatology; 2018 Jun; 18(4):407-412. PubMed ID: 29650332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of whole-lesion ADC histogram metrics for assessing the malignant potential of pancreatic intraductal papillary mucinous neoplasms (IPMNs).
    Hoffman DH; Ream JM; Hajdu CH; Rosenkrantz AB
    Abdom Radiol (NY); 2017 Apr; 42(4):1222-1228. PubMed ID: 27900458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of SOX9 in intraductal papillary mucinous neoplasms of the pancreas.
    Meng F; Takaori K; Ito T; Masui T; Kawaguchi M; Kawaguchi Y; Uemoto S
    Pancreas; 2014 Jan; 43(1):7-14. PubMed ID: 24212241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraductal papillary-mucinous tumor and mucinous cystic neoplasm: CT and MR findings.
    Itai Y; Minami M
    Int J Gastrointest Cancer; 2001; 30(1-2):47-63. PubMed ID: 12489580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography.
    Harima H; Kaino S; Shinoda S; Kawano M; Suenaga S; Sakaida I
    World J Gastroenterol; 2015 May; 21(20):6252-60. PubMed ID: 26034360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic Pancreatitis Finding by Endoscopic Ultrasonography in the Pancreatic Parenchyma of Intraductal Papillary Mucinous Neoplasms Is Associated with Invasive Intraductal Papillary Mucinous Carcinoma.
    Takenaka M; Masuda A; Shiomi H; Yagi Y; Zen Y; Sakai A; Kobayashi T; Arisaka Y; Okabe Y; Kutsumi H; Toyama H; Fukumoto T; Ku Y; Kudo M; Azuma T
    Oncology; 2017; 93 Suppl 1():61-68. PubMed ID: 29258092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the 2012 International Consensus Guidelines Using Computed Tomography and Magnetic Resonance Imaging: Branch Duct and Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Seo N; Byun JH; Kim JH; Kim HJ; Lee SS; Song KB; Kim SC; Han DJ; Hong SM; Lee MG
    Ann Surg; 2016 Mar; 263(3):557-64. PubMed ID: 25822687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas.
    Pedrazzoli S; Sperti C; Pasquali C; Bissoli S; Chierichetti F
    Ann Surg; 2011 Dec; 254(6):971-6. PubMed ID: 22076067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.
    Miyasaka Y; Ohtsuka T; Tamura K; Mori Y; Shindo K; Yamada D; Takahata S; Ishigami K; Ito T; Tokunaga S; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Ann Surg; 2016 Jun; 263(6):1180-7. PubMed ID: 26334637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does a family history of pancreatic ductal adenocarcinoma and cyst size influence the follow-up strategy for intraductal papillary mucinous neoplasms of the pancreas?
    Mandai K; Uno K; Yasuda K
    Pancreas; 2014 Aug; 43(6):917-21. PubMed ID: 24743378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.